For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target\r\ntrough blood level is 3ââ?¬â??8 Ã?µg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to\r\nmaintain blood levels of 5ââ?¬â??8 ug/L (designated RD group) and a cohort of 51 CTx patients with chronic kidney disease receiving\r\n0.5 mg bid to maintain blood levels of 3ââ?¬â??5 ug/L (designated LD group). The primary endpoint was a composite of death, rejection\r\nand premature EVL discontinuation up to 1 year after introduction of EVL. The primary endpoint was reached by 32% of patients\r\nin the LD group and by 41.1% of patients in the RD group (P = 0.361). Biochemical safety parameters were comparable in both\r\ngroups. Our results indicate that low-dose EVL may be as effective and safe as regular dose EVL.
Loading....